Silicon Valley thinks it can make humans live up to 200 years with AI and science

Silicon Valley's ultrawealthy have invested over $5 billion in longevity technology over the past 25 years, treating aging as a bug to be fixed through AI and biotech innovation.

Tech billionaires including Peter Thiel, Sam Altman, and Marc Andreessen are pouring massive funding into companies developing anti-aging solutions. Average fundraising rounds have jumped 20% to $43 million per deal, with some companies like Altos raising $3 billion. The investment spans three main areas: cell reprogramming and aging reversal, biotech drugs for age-related diseases, and immediate health optimization products.

• Peter Thiel alone has backed nearly a dozen longevity firms with over $700 million in combined funding
• Companies like NewLimit ($130M), Insilico Medicine ($500M+), and BioAge Labs ($559M) are using AI and biotech to tackle aging
• Personal motivations drive many investors, with some experiencing family losses to age-related diseases
• The longevity market includes everything from cell rejuvenation technology to health tracking wearables and nutrition plans